Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Term Eslicarbazepine Acetate Extension Study.

Next Previous
Search
Trial Profile

Long-Term Eslicarbazepine Acetate Extension Study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Sunovion Pharmaceuticals

    • Most Recent Events

    • 28 Apr 2017 Results of a post-hoc analysis (n=270) assessing efficacy and safety outcomes during the OLE for the 'true ESL monotherapy' subgroup, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results assessing Indices of Thyroid Function in patients from six phase III studies and their extensions (BIA2093-301,302,304,045,046,050; n=1812), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of six phase III studies and their extensions (BIA2093-301,302,304,045,046,050) presented at the 69th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top